Shi H, Xu H, Liang G
First Affiliated Hospital, Guangxi Medical University, Nanning.
Zhonghua Nei Ke Za Zhi. 1995 Nov;34(11):753-6.
An in vivo mouse model of allergic bronchial asthma was developed to investigate the effects of a platelet activating factor antagonist ONO-6240 on eosinophil (EOS) recruitment into the mouse airway. In the present study, no EOS could be found in bronchoalveolar lavage fluid (BALF) from normal control mice. However, chronic ovalbumin challenge of sensitized mice induced significant bronchoalveolar eosinophilia (9.68 +/- 0.72 x 10(8)/L). In three groups of mice treated intraperitoneally with different doses of ONO-6240 (0.1, 1.0, 10.0 mg/kg), the medication produced 42.1% (5.60 +/- 0.97 x 10(8)/L, P < 0.01), 58.8% (3.99 +/- 0.84 x 10(8)/L, P < 0.01), and 72.6% (2.65 +/- 0.71 x 10(8)/L, P < 0.01) inhibition, respectively, of the antigen-induced influx of EOS into BALF. It was found that the prevention of EOS infiltration into airway with ONO-6240 was accompanied by decrements of both interleukin (IL)-5 and IL-2 levels. These data indicated that ONO-6240 prevented airway eosinophilia by inhibiting production of IL-5 and IL-2. Our results suggested that ONO-6240 may be of value in treating human asthmatic patients.
为了研究血小板活化因子拮抗剂ONO - 6240对嗜酸性粒细胞（EOS）募集到小鼠气道中的影响，建立了变应性支气管哮喘的体内小鼠模型。在本研究中，正常对照小鼠的支气管肺泡灌洗液（BALF）中未发现EOS。然而，致敏小鼠经慢性卵清蛋白激发后，诱导出显著的支气管肺泡嗜酸性粒细胞增多（9.68±0.72×10⁸/L）。在三组分别腹腔注射不同剂量ONO - 6240（0.1、1.0、10.0 mg/kg）的小鼠中，该药物分别对抗原诱导的EOS流入BALF产生了42.1%（5.60±0.97×10⁸/L，P<0.01）、58.8%（3.99±0.84×10⁸/L，P<0.01）和72.6%（2.65±0.71×10⁸/L，P<0.01）的抑制作用。研究发现，ONO - 6240预防EOS浸润气道的同时，白细胞介素（IL）-5和IL - 2水平均降低。这些数据表明，ONO - 6240通过抑制IL - 5和IL - 2的产生来预防气道嗜酸性粒细胞增多。我们的结果提示，ONO - 6240可能对治疗人类哮喘患者有价值。
